ViGenCell KRX:308080KOSDAQ

바이젠셀 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked21since Sep 11

In Q3 2026, ViGenCell reported revenue of ₩566m, up 6972.9% year on year, and an operating loss of ₩2.6bn. ViGenCell (바이젠셀) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 4 with 8 articles. The most common catalyst was tech & capacity (2). It was most often mentioned alongside 글로벌테크놀로지 and L&C Bio.

Filing signals 4 quarters of losses Screener

ViGenCell today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates ViGenCell stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

ViGenCell quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩566m+6972.9%−₩2.6bn−₩2.4bn
Q2 2026₩571m+91691.0%−₩2.5bn−₩2.3bn
Q1 2026₩329m–−₩2.8bn−₩2.6bn
Q4 2025 derived₩14m-93.7%−₩6.3bn−₩6.1bn
Q3 2025₩8m+1500.2%−₩2.4bn−₩2.2bn
Q2 2025₩1m-98.9%−₩5.7bn−₩5.4bn
Q1 2025₩0m–−₩2.7bn−₩2.6bn
Q4 2024 derived₩223m–−₩3.7bn−₩3.7bn

ViGenCell ranks #2039 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

ViGenCell top stories 2 weeks, by number of outlets

  1. 1
    BaizenCell participates in Bio Europe seeking cell therapy technology transfer
    2 outlets · 2 articlesFirst report Nov 4 11:04 메디파나뉴스Licensing deal
  2. 2
    Vigen Cell heads to Europe with three anti-cancer cell therapies, seeking co-development partners
    1 outlets · 1 articlesFirst report Nov 4 10:24 이데일리Partnership
  3. 3
    Biocell: pursuing sales of cell therapy in Europe while seeking co-development opportunities
    1 outlets · 1 articlesFirst report Nov 4 16:03 한스경제Partnership
  4. 4
  5. 5
  6. 6
    Biozensell participates in BioEurope…showcases autologous and allogeneic cell therapies
    1 outlets · 1 articlesFirst report Nov 4 11:20 머니투데이

Latest ViGenCell news Korean headlines